H1抗组胺药与接受免疫检查点抑制剂治疗的肿瘤患者预后关系的meta分析

doi:10.3969/j.issn.1004-583X.2025.08.002

摘要/Abstract

摘要：

目的探讨H1抗组胺药对接受免疫检查点抑制剂治疗的癌症患者生存期的影响。方法在中国知网、万方、PubMed、Web of Science和Cochrane数据库检索2024年10月30日前发表的有关H1抗组胺药影响癌症患者免疫检查点抑制剂治疗疗效的文献,采用RevMan 5.4和Stata 14.0软件进行统计分析。结果总共有4项研究被纳入荟萃分析,结果显示,与未服用H1抗组胺药的患者相比,同时服用H1抗组胺药有助于延长接受免疫检查点抑制剂治疗者的总生存期(HR=0.53,95%CI: 0.41~0.69,P<0.00001)和无进展生存期(HR=0.54,95%CI: 0.44~0.65,P<0.00001)。结论在免疫检查点抑制剂治疗期间,联合使用抗组胺药能改善癌症患者的预后。

关键词: H1抗组胺药, 免疫检查点抑制剂, 预后, Meta分析

Abstract:

Objective To explore the impact of H1-antihistamines on the survival of cancer patients receiving immune checkpoint inhibitors (ICIs). Methods Articles on the efficacy of H1-antihistamines on immune checkpoint inhibitor therapy in cancer patients published before October 30, 2024 were searched in the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, Web of Science and Cochrane databases. Statistical analysis was performed using RevMan 5.4 and Stata14.0 software. Results Four studies were included in the meta-analysis. The results showed the patients treated H1-antihistamines with ICIs had significantly longer overall survival (OS) (HR=0.53, 95%CI: 0.41-0.69, P<0.00001) and progression-free survival (PFS) (HR=0.54, 95%CI: 0.44-0.65, P<0.00001) in comparison with those not receiving H1-antihistamines. Conclusion The concomitant use of H1-antihistamines is associated with improved outcomes among cancer patients treated with ICIs.

Key words: H1-antihistamines, immune checkpoint inhibitors, prognosis, meta-analysis

中图分类号:

R971.9

叶倩, 刘申香. H1抗组胺药与接受免疫检查点抑制剂治疗的肿瘤患者预后关系的meta分析[J]. 临床荟萃, 2025, 40(8): 684-688.

Ye Qian, Liu Shenxiang. A meta-analysis of the relationship between H1-antihistamines and prognosis in cancer patients receiving immune checkpoint inhibitor therapy[J]. Clinical Focus, 2025, 40(8): 684-688.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.08.002

https://www.lchc.cn/CN/Y2025/V40/I8/684

图/表 5

图1 文献筛选流程图

Fig.1 Flow diagram of literature selection process

表1 纳入研究的特征

Tab.1 Characteristics of included studies

第一作者	发表年份	地区	患者数量 (服用/未服用 H1抗组胺药)	肿瘤类型	H1抗组胺药类型	ICIs类型	临床结局
Chiang^[5]	2023	中国台湾	336(294/42)	肺癌	阳离子两亲性抗组胺药/非阳离子两亲性抗组胺药	PD-1/PD-L1	PFS
Mallardo^[6]	2022	苏格兰	121(71/50)	黑色素瘤	西替利嗪	PD-1	OS、PFS
EylemerMocan^[7]	2023	土耳其	133(55/78)	黑色素瘤/肾细胞癌/非小细胞肺癌/其他	扑尔敏/西替利嗪/地氯雷他定/非索非那定	PD-1/PD-L1/CTLA-4	OS、PFS
Zhang^[8]	2024	中国	211(109/102)	肺癌	苯海拉明	PD-1/PD-L1	OS、PFS

图2 H1抗组胺药对接受ICIs治疗患者OS影响的森林图

Fig.2 Forest plots showing the effect of H1 antihistamines on the OS in patients receiving ICIs

图3 H1抗组胺药对接受ICIs治疗患者PFS影响的森林图

Fig.3 Forest plots showing the effect of H1 antihistamines on the PFS in patients receiving ICIs

图4 H1抗组胺药对接受ICIs治疗患者影响的漏斗图 a.OS;b.PFS

Fig.4 Funnel plots showing the effect of H1 antihistamines on the OS (a) and PFS (b) in patients receiving ICIs

参考文献 19

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[2]	Sharma P, Wagner K, Wolchok J D, et al. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps[J]. Nat Rev Cancer, 2011, 11(11):805-812. doi: 10.1038/nrc3153 pmid: 22020206
[3]	Yang M, Wang Y, Yuan M, et al. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis[J]. Int Immunopharmacol, 2020, 88:106876.
[4]	Li H, Xiao Y, Li Q, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1[J]. Cancer Cell, 2022, 40 (1):36-52.e9.
[5]	Chiang CH, Chiang CH, See XY, et al. The impact of cationic amphiphilic antihistamines on patients with lung cancer receiving immunotherapy[J]. J Clin Oncol, 2023, 41 (16_suppl):e21078-e21078.
[6]	Mallardo D, Simeone E, Vanella V, et al. Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization[J]. J Transl Med, 2022, 20(1):436. doi: 10.1186/s12967-022-03643-w pmid: 36180872
[7]	Eylemer Mocan E, Yekedüz E, Karataş G, et al. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients[J]. Anticancer Drugs, 2023, 35(2):190-194.
[8]	Zhang WH, Li BX, Ma CX, et al. Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: A cohort study[J]. Transl Lung Cancer Res, 2024, 13(10):2787-2801.
[9]	Hussain N, Naeem M, Pinato DJ. Concomitant medications and immune checkPoint inhibitor therapy for cancer: Causation or association?[J]. Human Vaccin Immunother, 2020, 17 (1):55-61.
[10]	Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events[J]. Eur J Cancer, 2021, 157 :474-484.
[11]	Plaut M. Histamine, H1 and H2 antihistamines, and immediate hypersensitivity reactions[J]. J Allergy Clin Immunol, 1979, 63(6):371-375.
[12]	Graff L, Frungieri M, Zanner R, et al. Expression of histidine decarboxylase and synthesis of histamine by human small cell lung carcinoma[J]. Am J Pathol, 2002, 160 (5):1561-1565. pmid: 12000707
[13]	von Mach-Szczypiński J, Stanosz S, Sieja K, et al. Metabolism of histamine in tissues of primary ductal breast cancer[J]. Metabolism, 2009, 58 (6):867-870.
[14]	Anagnostou VK, Brahmer JR. Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer[J]. Clin Cancer Res, 2015, 21(5):976-984. doi: 10.1158/1078-0432.CCR-14-1187 pmid: 25733707
[15]	Zhang L, Zhang M, Xu J, et al. The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: A narrative review[J]. Ann Transl Med, 2020, 8(22):1526. doi: 10.21037/atm-20-6719 pmid: 33313271
[16]	Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice[J]. Nat Rev Immunol, 2020, 20(11):651-668.
[17]	Petersen NH, Olsen OD, Groth-pedersen L, et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase[J]. Cancer Cell, 2013, 24(3):379-393. doi: 10.1016/j.ccr.2013.08.003 pmid: 24029234
[18]	Anand A, Liu B, Dicroce Giacobini J, et al. Cell death induced by cationic amphiphilic drugs depends on lysosomal Ca²⁺ release and cyclic AMP[J]. Mol Cancer Ther, 2019, 18(9):1602-1614. doi: 10.1158/1535-7163.MCT-18-1406 pmid: 31285280
[19]	Ellegaard AM, Dehlendorff C, Vind AC, et al. Repurposing cationic amphiphilic antihistamines for cancer treatment[J]. EBioMedicine, 2016, 9:130-139.